A retatrutide protocol, in the only sense that has ever existed, is a clinical trial document: a written plan describing who may enrol, what they receive, how they are watched, and what gets measured. One such plan produced the result people are actually searching for, published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues.
The vendor we point lifters to
Retatrutide from Ascension Peptides
Independently assayed material, dispatched from the US. Both vial sizes drop by half with the code below.
The certificate that resolves for this compound is MZ Biolabs lot 03-01260229, reporting 99.94 percent purity and 11.67 mg against a 10 mg label, purity and quantity only, with no endotoxin or sterility screen. A second certificate is linked on the product page and does not load. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- One resolving lab report per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 9, 2026.
The other sense of the word, a schedule someone posts and someone else follows, has no document behind it. That distinction is not pedantry. It is the difference between a plan with exclusion criteria and a plan without them.
One thing belongs ahead of the detail: retatrutide is unapproved in every market. No regulator has licensed it, no pharmacy can dispense it, and no schedule of the second kind attaches to a product anyone can lawfully obtain.
Two different things share the word
Say a lifter reads that the highest arm of the Phase 2 trial produced roughly 24 percent mean weight reduction at 48 weeks. They then find a forum post giving an amount and a schedule. It looks like the same information transferred into usable form.
It is not. What transferred was the number. What stayed behind was the apparatus that made the number interpretable: the screening that decided who was allowed near the drug, the supervision that caught problems, the discontinuation rules, the laboratory monitoring, and the trained observers writing down every adverse event whether or not the participant thought it mattered.
A trial protocol is mostly not the dose. The dose is one line in a document whose other purpose is to define the conditions under which that line is defensible.
What the retatrutide protocol in the published trial contained
Broadly, and without turning any of it into instructions, the design was a randomised, placebo controlled Phase 2 study in adults with obesity, run across multiple sites, with participants assigned to placebo or to one of several dose arms including the 12 mg arm that produced the headline figure. Doses were escalated gradually under supervision rather than started at target, because the tolerability of this drug class is dose related in humans. The primary outcome was change in body weight, assessed at 48 weeks. The Phase 3 programme, TRIUMPH, is ongoing.
Every element there is a trial fact. None of it is a recommendation, and reporting a trial arm is not the same as endorsing it.
| Element of the trial plan | Survives when a schedule is copied | What its absence changes |
|---|---|---|
| Eligibility screening and exclusions | No | An unscreened person may carry a contraindication nobody looked for |
| Supervised gradual escalation | Sometimes, badly | Tolerability in this class is dose related, and going too fast is where people fail |
| Scheduled clinician review | No | Problems are caught by the user, who is also the person motivated to continue |
| Recorded adverse events | No | Nothing is learned, by anyone, from what goes wrong |
| Verified drug identity and concentration | No | An unapproved product has no pharmacopoeial standard behind it |
| Defined stopping rules | No | The decision to stop happens under sunk cost pressure |
Questions that come before the rest of this makes sense
Is there any published protocol a person could follow?
No. Published trial documents describe supervised research conditions, and there is no approved product, no licensed indication and no dispensing route in any market.
Does the trial evidence make a copied schedule reasonable?
The evidence is about outcomes in a monitored population. It says nothing about outcomes in an unmonitored one, which is the population doing the copying.
Was the escalation the interesting part?
It was the tolerability management, not the mechanism. It exists because the unwanted effects of this class track dose in humans, which is a reason for caution rather than a technique to borrow.
Did any arm include a training programme?
No published arm of this work was designed around resistance training. The interaction between this drug and a lifting programme is unstudied.
Does an ongoing Phase 3 programme change the status?
Not yet. An ongoing programme is a reason to expect better information later, not evidence that the current information is sufficient.
The part a copied schedule silently deletes
There is a specific failure mode worth naming, because it is invisible from inside.
Trials of this class in humans report gastrointestinal effects, nausea, vomiting, diarrhoea and constipation, as the most common problem, and they are dose related. In the trial setting, a participant who cannot eat says so, a clinician adjusts or stops, and the event is recorded.
Outside that setting, the same person interprets the inability to eat as the drug working. The signal that would trigger a pause in a trial becomes, in a forum context, the evidence of success. That inversion is the mechanism by which a copied schedule produces a worse outcome than the same amount produced under supervision, even when the milligrams match exactly.
For a lifter it compounds. Days of low intake in the middle of a training block are days of low protein and poor recovery, at exactly the point where the deficit is already pulling on lean tissue.
Body composition was not what this design was built to measure
The primary endpoint was body weight. That is the correct endpoint for the question the trial asked, and it is the wrong endpoint for the question this audience has.
Weight is a sum. It contains fat, water, glycogen, gut contents and lean tissue, and a scale cannot separate them. Body composition substudies of related incretin drugs in humans have reported that a meaningful share of total weight lost is fat free mass rather than fat, and fat free mass itself is a mixed category: part of it is fluid and glycogen that returns, part of it is contractile tissue that does not.
Because retatrutide moves more total mass than earlier agents, the absolute quantity in that fat free column is larger even if the proportion turns out to be similar. That is the honest framing. Not that the drug is uniquely destructive to muscle, but that the size of the effect makes the accounting matter more.
What the trial ran it on, and how that differs from this reader
The second half of the phrase matters as much as the first. A protocol is always a protocol for someone.
This work enrolled adults with obesity, and in the wider programme adults with obesity and related metabolic conditions. That population has a large amount of fat mass available to lose and, on average, a lower baseline of trained muscle to defend. For them the arithmetic of a steep deficit is favourable, because the fat compartment is deep enough to absorb most of the demand.
A forty year old lifter carrying visible abdominal fat over a decade of accumulated muscle is a different starting position. Less fat mass is available, so a deficit of the same depth pulls proportionally harder on everything else. The tissue at risk is also the tissue they came for.
None of the published work speaks to that person. It was not designed to, and the fact that the drug demonstrably works in the population studied does not tell you what it does to body composition in a population with a different starting composition. That is not a criticism of the trial. It is a description of what a trial is: an answer to one question, asked of one group.
The study a lifter would actually want, and nobody has run
It would randomise trained adults to the drug or placebo, hold a structured resistance programme constant across groups, control protein intake, measure body composition rather than weight, and report strength alongside mass. It would follow people past discontinuation to see what the regained weight was made of.
None of that exists for this compound. What exists instead are two separate literatures that have never been joined: a drug literature reporting large weight reduction in humans, and a training and nutrition literature reporting that resistance work and adequate protein preserve lean mass in humans losing weight conventionally.
Reasoning across the gap is not unreasonable. It is just not evidence, and it should be labelled as the inference it is.
Where this leaves someone reading a forum post
The compound has genuine human efficacy data, which is rare in this category and worth saying plainly. It also has no approval anywhere, no verified supply, and no protocol in the sense the searcher means.
Someone reading a posted schedule is reading a number stripped of the structure that made it interpretable, applied to a body nobody screened, monitored by a person with an obvious interest in continuing, in pursuit of a scale reading that does not distinguish the tissue they want to lose from the tissue they spent a decade building.
That is a defensible thing to describe accurately. It is not a defensible thing to present as a plan.